Gadolinium Market Size was valued at USD 5.2 Billion in 2022. The gadolinium industry is projected to grow from USD 5.48 Billion in 2023 to USD 8.41 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.50% during the forecast period (2024 - 2032). Increased technological developments and increased demand from the healthcare industry are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
One prominent trend in the gadolinium market is the increasing demand for gadolinium-based contrast agents (GBCAs) in medical imaging. Gadolinium's unique properties make it valuable in enhancing the visibility of internal body structures during magnetic resonance imaging (MRI). The rising prevalence of diseases, coupled with the advancements in diagnostic imaging technologies, is driving the use of gadolinium in medical applications, particularly in enhancing the accuracy of diagnostic procedures. This factor drives the market CAGR.
Additionally, an emerging trend involves a shift towards developing and adopting gadolinium-free contrast agents. Concerns about the potential long-term retention of gadolinium in the body have prompted research and development efforts to explore alternative contrast agents that do not rely on gadolinium. This trend reflects the industry's commitment to addressing safety and regulatory concerns while maintaining the efficacy of contrast-enhanced imaging techniques.
Beyond medical applications, another trend is the exploration of gadolinium's utility in various sectors. Gadolinium finds use in the electronics industry for enhancing the properties of magnetic materials. The demand for high-performance electronic devices is fueling the incorporation of gadolinium-based materials in the production of components like magnetic sensors and memory devices. This diversification of gadolinium applications showcases its versatility and the potential for market growth beyond the traditional medical imaging sector. For instance, Guerbet Group, in 2021, acquired Accurate Medical Therapeutics for an undisclosed amount. The primary objective behind this acquisition was to enhance Guerbet's interventional radiology business by incorporating Accurate's microcatheter technology into its existing product portfolio. Thus, driving the gadolinium market revenue.
The gadolinium market segmentation, based on type, includes Gadolinium Acetate, Gadolinium Acetylacetonate, Gadolinium Oxide, Gadolinium Nitrate, Gadolinium Chloride, and Others. The dominating category is gadolinium oxide, holding a prominent position in the market due to its widespread application in various industries, including electronics, healthcare, and catalysis. Gadolinium Oxide is extensively used in the production of phosphors for electronics and magnetic resonance imaging (MRI) contrast agents in the medical field, contributing to its dominant market presence. Meanwhile, the fastest-growing category is Gadolinium Chloride, driven by increasing demand for gadolinium-based compounds in industrial processes and research applications.
The gadolinium market segmentation, based on Application, includes Electronics, Medical Equipment, Imaging Agents, Nuclear Reactors, and Others. The dominating category is electronics, primarily fueled by the widespread use of gadolinium compounds, such as Gadolinium Oxide, in the production of phosphors for electronic devices. The electronics sector benefits from gadolinium's unique magnetic and luminescent properties, making it an essential component in various electronic applications. On the other hand, the fastest-growing category is Medical Equipment, driven by the increasing demand for gadolinium-based imaging agents in the healthcare industry, especially in magnetic resonance imaging (MRI).
Figure 1: Gadolinium Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American gadolinium market area will dominate this market, owing to ongoing research and development activities in the pharmaceutical and healthcare sectors, which will boost market growth in this region.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2: GADOLINIUM MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe gadolinium market accounts for the second-largest market share due to the well-established healthcare system with advanced medical imaging facilities and a high prevalence of diagnostic procedures. Further, the German gadolinium market held the largest market share, and the UK gadolinium market was the fastest growing market in the European region
The Asia-Pacific Gadolinium Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to increasing investments in healthcare infrastructure, coupled with a rising prevalence of diseases and disorders requiring advanced diagnostic imaging. Moreover, China’s gadolinium market held the largest market share, and the Indian gadolinium market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the gadolinium market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, gadolinium industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the gadolinium industry to benefit clients and increase the market sector. In recent years, the gadolinium industry has offered some of the most significant advantages. Major players in the gadolinium market, including Goodfellow Corporation, GFS Chemicals, Inc., All-Chemie, Ltd, Pascal Technologies, Inc., Fredericksburg, VA Alfa Chemical Corporation, Molycorp., and others, are attempting to increase market demand by investing in research and development operations.
Bracco Imaging S.p.A. is a leading global company specializing in diagnostic imaging. Established in 1927 and headquartered in Milan, Italy, Bracco is recognized for its innovative contrast agents and advanced medical imaging technologies. The company operates in various segments, including radiology, cardiology, and interventional imaging. Bracco's commitment to research and development has positioned it as a key player in the healthcare industry, contributing to advancements in diagnostic imaging. With a global presence and a diverse portfolio of imaging solutions, Bracco Imaging S.p.A. continues to play a crucial role in enhancing medical diagnostics and patient care worldwide. In 2021, Bracco Imaging S.p.A. made a significant move by acquiring Blue Earth Diagnostics Ltd. for $450 million. This strategic acquisition was aimed at broadening Bracco's oncology portfolio through the addition of a new diagnostic agent utilized in prostate cancer imaging.
GE Healthcare is a global leader in the healthcare industry, providing a wide range of medical technologies, diagnostic imaging, and healthcare solutions. Established as a division of General Electric (GE), GE Healthcare operates with a mission to improve access to quality healthcare worldwide. The company offers innovative products and services across various healthcare segments, including medical imaging, diagnostics, pharmaceutical diagnostics, and life sciences. GE Healthcare is known for its commitment to research and development, driving advancements in medical technology to address evolving healthcare challenges. In 2020, GE Healthcare entered into a strategic partnership with Vanderbilt University Medical Center. This collaboration was centered around the development of AI-powered imaging software designed for personalized cancer care. The overarching goal was to advance the precision and personalization of cancer diagnosis and treatment.
In May 2023, GE Healthcare divulged that it had struck a strategic agreement with Syntellix AG, a company that specializes in making bio-absorbable materials, in a bid to create fresh MRI contrast agents based on gadolinium. The common strategy of these partnerships is to reduce the amount of gadolinium retained in the body and subsequently improve the safety of MRI contrast agents. The collaboration is anticipated to spur new non-invasive imaging techniques for improving patient care.
In June 2023, Bracco Imaging launched a brand-new adavsiatous gadolinium contrast under the trademark VUEWAY in Europe. This new agent was developed to facilitate enhanced diagnostic imaging with reduced retention of gadolinium in tissues. Bracco pointed out the relevance of the product launch to the European Medicines Agency guidelines on the safety of GBCAs.
In August 2023, Guerbet Group, a French biotechnology firm, raised the GBCA manufacturing capacity in the USA. The company extended its Cincinnati plant investments by $50 million in order to service the growing MRI market in North America. The adavsiatous expansion will help the firm serve its gadolinium contrast agents, such as Dotarem® and Artirem® more effectively to the market.
In September 2023, Canon Medical Systems Corporation announced the launch of the research aimed at developing new types of MRI contrast agents based on gadolinium. Experts from the company in Japan are trying to evolve a more stable gadolinium complex so as to cut down on the side effects relative to toxicity and improve imaging. The initiative is part of a wider campaign that is being undertaken by Canon Medical to be at the cutting edge of diagnostic imaging technologies.
In October 2023, the global diagnostic imaging leader Lantheus Holdings announced a partnership with Cleveland Diagnostics in a new joint venture, which will identify novel applications of gadolinium-based agents in the treatment of cancer. This partnership will target the development of contrast agents, which would facilitate the MRI-based early diagnosis of select cancers. The companies plan to submit a product for clinical development application by the end of 2024.
In November 2023, A collaborative effort by Siemens Healthineers and NVIDIA focused on whether artificial intelligence (AI) could help determine the optimal dose of gadolinium for MRIs. This AI approach provides a solution to this conflict by seeking to decrease the volume of gadolinium used to achieve a good-quality image while addressing the difficulty of gadolinium retention. This study was part of the real-world application of AI in medical imaging, which was one of the strategies by Siemens, to enhance the use of AI in medical imaging.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 5.2 Billion |
| Market Size 2023 | USD 5.48 Billion |
| Market Size 2032 | USD 8.41 Billion |
| Compound Annual Growth Rate (CAGR) | 5.50% (2024-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia-Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Goodfellow Corporation, GFS Chemicals, Inc., All-Chemie, Ltd, Pascal Technologies, Inc., Fredericksburg, VA Alfa Chemical Corporation, Molycorp |
| Key Market Opportunities | · Increased technological developments |
| Key Market Dynamics | · Increased demand from the healthcare industry |
Frequently Asked Questions (FAQ) :
The gadolinium market size was valued at USD 5.2 Billion in 2022.
The global market is projected to grow at a CAGR of 5.50% during the forecast period, 2024-2032.
North America had the largest share in the global market
The key players in the market are Goodfellow Corporation, GFS Chemicals, Inc., All-Chemie, Ltd, Pascal Technologies, Inc., Fredericksburg, VA Alfa Chemical Corporation, and Molycorp.
The Gadolinium Oxide category dominated the market in 2022.
The Electronics based had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Team Lead - Research Anshula mandaokar holds an academic degree in chemical engineering and has been contributing to the field for more than 5 years. she has expertise in market research and business consulting and serves as a team lead for a reputed market research firm under the chemicals and materials domain spectrum. she has worked on multiple projects, generating explicit results in a quick turnaround time. her understanding of data interpretation justifies her role as a leader.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
